Platinum Investment Management LTD Blueprint Medicines Corp Transaction History

Platinum Investment Management LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	SELL	$46.9 - $66.0 $2.4 Million - $3.38 Million	-51,153 Reduced 91.07%	5,018 $252,000
Q1 2023 May 11, 2023	BUY	$37.97 - $50.0 $620,012 - $816,450	16,329 Added 40.98%	56,171 $2.53 Million
Q4 2022 Feb 13, 2023	BUY	$41.06 - $66.48 $286,598 - $464,030	6,980 Added 21.24%	39,842 $1.75 Million
Q3 2022 Nov 14, 2022	SELL	$49.93 - $77.7 $356,600 - $554,933	-7,142 Reduced 17.85%	32,862 $2.17 Million
Q2 2022 Aug 11, 2022	BUY	$45.23 - $70.15 $582,698 - $903,742	12,883 Added 47.5%	40,004 $2.02 Million
Q4 2020 Feb 12, 2021	SELL	$92.08 - $124.48 $1.14 Million - $1.54 Million	-12,390 Reduced 31.36%	27,121 $3.04 Million
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $982,261 - $1.68 Million	20,417 Added 106.93%	39,511 $2.31 Million
Q4 2019 Feb 13, 2020	BUY	$66.73 - $82.59 $423,602 - $524,281	6,348 Added 49.8%	19,094 $1.53 Million
Q1 2019 May 15, 2019	BUY	$48.7 - $86.6 $620,730 - $1.1 Million	12,746 New	12,746 $1.02 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Platinum Investment Management LTD, based on Form 13F filings with the SEC.

Stay updated on Platinum Investment Management LTD with notifications on news.